Search

Search Results

Results 9101 - 9110 of 9583 for Action potential

SCHIP has been successful in increasing access to health care for low income children

News - 24 Apr 2007

As the debate over reauthorization of the State Children's Health Insurance Program (SCHIP) heats up in Washington, a new survey of leaders in health policy and health care finds that large majorities...
FDA statement on foodborne E. coli O157:H7 outbreak in spinach

News - 8 Oct 2006

To date, 199 cases of illness due to E. coli O157:H7 infection have been reported to CDC, including 31 cases of Hemolytic Uremic Syndrome (HUS), 102 hospitalizations and three deaths.
New plan to confront HIV-related health worker shortages

News - 15 Aug 2006

Launch of a coordinated global plan to address a major and often overlooked barrier to preventing and treating HIV/AIDS: the severe shortage of health workers, particularly in developing nations.
Severe Acute Respiratory Syndrome (SARS) overview

News - 24 Apr 2004

Severe Acute Respiratory Syndrome (SARS) is an atypical form of pneumonia that first appeared in November 2002 in Guangdong Province, China.
Paxam

Drug - 4 Jun 2026

Consumer Medicine Information (CMI) about Paxam intended for persons living in Australia.
Kalma

Drug - 3 Jun 2026

Consumer Medicine Information (CMI) about Kalma intended for persons living in Australia.
Zempreon CFC-Free Inhaler

Drug - 29 May 2026

Consumer Medicine Information (CMI) about Zempreon CFC-Free Inhaler intended for persons living in Australia.
Asmol CFC-Free Inhaler (with counter)

Drug - 29 May 2026

Consumer Medicine Information (CMI) about Asmol CFC-Free Inhaler (with counter) intended for persons living in Australia.
Scemblix

Drug - 27 May 2026

Consumer Medicine Information (CMI) about Scemblix intended for persons living in Australia.
Cenrifki

Drug - 25 May 2026

Consumer Medicine Information (CMI) about Cenrifki intended for persons living in Australia.

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.